Bioventus, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Axogen, Inc.

Bioventus, Inc.

NeuroPace, Inc.

908 Devices, Inc.

ZimVie, Inc.

Butterfly Network, Inc.

Standard BioTools, Inc.

Allurion Technologies, Inc.

Celcuity, Inc.

Pulse Biosciences, Inc.

Alpha Tau Medical Ltd.

Why is Bioventus, Inc. ?

Strong Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 7.84%

The company declared negative results in Mar'25 after very positive results in Dec'24

NET PROFIT(HY) At USD 5.07 MM has Grown at -30.64%

With ROE of 1.08%, it has a risky valuation with a 3.71 Price to Book Value

Over the past year, while the stock has generated a return of -32.26%, its profits have risen by 115.7% ; the PEG ratio of the company is 3

High Institutional Holdings at 79.51%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 3.51% over the previous quarter.

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -32.26% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Bioventus, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Bioventus, Inc. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Bioventus, Inc.

-35.53%

0.35

58.31%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

15.07%

EBIT Growth (5y)

21.62%

EBIT to Interest (avg)

2.27

Debt to EBITDA (avg)

4.88

Net Debt to Equity (avg)

2.20

Sales to Capital Employed (avg)

0.99

Tax Ratio

13.26%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

79.51%

ROCE (avg)

7.84%

ROE (avg)

6.25%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

345

Industry P/E

Price to Book Value

3.71

EV to EBIT

27.47

EV to EBITDA

10.75

EV to Capital Employed

1.85

EV to Sales

1.54

PEG Ratio

3.00

Dividend Yield

ROCE (Latest)

6.72%

ROE (Latest)

1.08%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

20What is working for the Company

NET PROFIT(Q)

At USD 7.68 MM has Grown at 591.44%

OPERATING CASH FLOW(Y)

Highest at USD 36.25 MM

ROCE(HY)

Highest at -0.1%

INTEREST COVERAGE RATIO(Q)

Highest at 409.25

RAW MATERIAL COST(Y)

Fallen by -1.5% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at 203.26 %

OPERATING PROFIT(Q)

Highest at USD 30.67 MM

OPERATING PROFIT MARGIN(Q)

Highest at 20.77 %

PRE-TAX PROFIT(Q)

Highest at USD 10.56 MM

EPS(Q)

Highest at USD 0.11

-6What is not working for the Company

NET PROFIT(HY)

At USD 5.07 MM has Grown at -30.64%

Here's what is working for Bioventus, Inc.

Pre-Tax Profit

At USD 10.56 MM has Grown at 998.69%

over average net sales of the previous four periods of USD -1.18 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 7.68 MM has Grown at 591.44%

over average net sales of the previous four periods of USD 1.11 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Interest Coverage Ratio

Highest at 409.25

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Cash Flow

Highest at USD 36.25 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit

Highest at USD 30.67 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at 20.77 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD 10.56 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

EPS

Highest at USD 0.11

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debt-Equity Ratio

Lowest at 203.26 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -1.5% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales